First Trust Advisors LP Purchases 57,941 Shares of United Therapeutics Co. (UTHR)

First Trust Advisors LP lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 12.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 522,093 shares of the biotechnology company’s stock after purchasing an additional 57,941 shares during the quarter. First Trust Advisors LP owned 1.21% of United Therapeutics worth $77,244,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Quantbot Technologies LP grew its position in United Therapeutics by 537.3% in the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 822 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new stake in United Therapeutics in the third quarter valued at $156,000. SeaCrest Wealth Management LLC bought a new stake in United Therapeutics in the fourth quarter valued at $178,000. HL Financial Services LLC bought a new stake in United Therapeutics in the fourth quarter valued at $217,000. Finally, CIBC Asset Management Inc bought a new stake in United Therapeutics in the fourth quarter valued at $220,000.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,253 shares of the stock in a transaction dated Friday, November 24th. The stock was sold at an average price of $124.07, for a total value of $155,459.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 580 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the completion of the transaction, the director now directly owns 1,555 shares in the company, valued at approximately $209,489.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,075 shares of company stock worth $393,760. 7.80% of the stock is owned by company insiders.

United Therapeutics Co. (UTHR) opened at $136.92 on Thursday. The stock has a market capitalization of $5,581.57, a PE ratio of 11.39 and a beta of 1.26. United Therapeutics Co. has a 1-year low of $112.01 and a 1-year high of $169.89.

UTHR has been the topic of a number of analyst reports. HC Wainwright reiterated a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a research report on Thursday, October 26th. Cowen reiterated a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research report on Friday, October 27th. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $140.27.

TRADEMARK VIOLATION WARNING: This report was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/02/15/first-trust-advisors-lp-purchases-57941-shares-of-united-therapeutics-co-uthr.html.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply